Severe Obesity and Established Cardiovascular Disease TRIUMPH-3 (NCT05882045) evaluated 1,949 adults with Class II or Class III obesity (body mass index of at least 35 kg/m) and established cardiovascular disease, with or without type 2 diabetes
Even trace levels can trigger severe inflammatory reactions, making reliable detection a core requirement in biopharmaceutical quality control
Typically, 812 sessions, taken once a week, followed by maintenance doses, show noticeable improvement
It is commonly used as supportive therapy in male reproductive health and may also contribute to general cardiovascular and metabolic well-being
Trulicity usually begins at its therapeutic dose
Patients taking the drug for weight loss reportedly experience an average of only 6 pounds of weight loss after one year of treatment